Article Text
Statistics from Altmetric.com
Introduction
Infantile fibrosarcoma (IFS) is a soft tissue tumour of intermediate malignant potential that commonly affects the extremities of young children and is characterised by an ETV6::NTRK3 fusion.1 2
Recurrent copy number changes, including the gain of chromosomes 8, 17 and 20, have been reported in IFS,3–5 but pathogenic mutations in other pathways are rare in this tumour type.6
We previously reported on a 5-year-old male patient with IFS of the right gluteal region/pelvis treated with chemotherapy, radiotherapy and TRK inhibition who developed metastatic, progressive disease with multiple acquired mutations, including TP53, SUFU and an NTRK F617L gatekeeper mutation.7 Due to acquired larotrectinib resistance, he was started on repotrectinib (according to phase I/II study NCT04094610 protocol).8 In this follow-up report, we describe the transformation (dedifferentiation) of the patient’s IFS to a high-grade osteosarcoma.
Report
The patient initially presented at 5 months of age with a mass on the right buttocks. Histological assessment of the ultrasound-guided biopsy tissue showed a cellular spindle cell neoplasm, which was positive for ETV6 rearrangement by fluorescence in situ hybridisation (FISH) and had an ETV6::NTRK3 fusion identified by reverse transcriptase PCR (RT-PCR), supporting a diagnosis of IFS (figure 1A).
Footnotes
Handling editor David Creytens.
Contributors LVF and TS conceptualised the study. JG, RM, LJT, MK and ASP provided clinical care of the patient and clinical data. TS, SCK and RER performed histopathological evaluation and provided histopathology data. LVF and ZS analysed the molecular data. LVF interpreted the molecular data and wrote the original draft. TS and ZRA assembled the figures. All authors reviewed the writing and edited the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.